Sanofi Announces Breakthroughs in Multiple Myeloma and MS Treatments

New Sarclisa Subcutaneous Formulation

Sanofi's new subcutaneous formulation of Sarclisa has met co-primary endpoints in the IRAKLIA phase 3 study, marking a significant advancement in the treatment of multiple myeloma. This development offers hope for patients seeking more effective treatment options.

Tolebrutinib Designated Breakthrough Therapy

The FDA has designated Tolebrutinib as a Breakthrough Therapy for non-relapsing secondary progressive multiple sclerosis (SPMS). This designation underscores the potential of Tolebrutinib to address a significant unmet need in the SPMS community, offering a new avenue for treatment.

Sarclisa Recommended for EU Approval

Sarclisa has been recommended for EU approval by the CHMP for the treatment of transplant-ineligible newly diagnosed multiple myeloma. This recommendation is a critical step towards making Sarclisa available to a broader patient population in need of effective treatment options.

Dupixent's Expansion in Treatment Options

Dupixent has seen a series of positive developments, including the acceptance of its sBLA for FDA review for chronic spontaneous urticaria and its approval in the EU as the first and only medicine for young children with eosinophilic esophagitis. These milestones highlight Dupixent's growing role in addressing a range of conditions with significant unmet needs.

Sanofi's Strategic Collaborations and Investments

Sanofi has also been active in expanding its capabilities and partnerships, including the initiation of a phase 3 program for PCV21 in collaboration with SK bioscience and a significant investment in bioproduction in France. These efforts reflect Sanofi's commitment to advancing healthcare through innovation and collaboration.